PARP (Poly ADP-ribose Polymerase) Inhibitors Market

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Report: By Drugs Type (Talazoparib, Veliparib, Olaparib, Others), Indication Type (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), and Region (North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa) Global Industry Analysis, Size, Share, Growth, Trends, Regional Analysis, Competitor Analysis and Forecast 2024-2032.

Pharma & Healthcare | January 2024 | Report ID: EMR00492 | Pages: 301

Global PARP (Poly ADP-ribose Polymerase) Inhibitors market is predicted to reach approximately USD 21.52 billion by 2032, at a CAGR of 11.08%from 2024 to 2032.

PARP inhibitors are a class of drugs designed to interfere with the activity of poly ADP-ribose polymerase enzymes, which play a crucial role in DNA repair. The primary purpose of these inhibitors is to selectively target cancer cells, particularly those with deficiencies in the BRCA genes, as they rely heavily on the PARP pathway for DNA repair. This innovative therapeutic approach has gained substantial attention in the oncology field, with applications extending across various cancer types.

The market for PARP inhibitors has witnessed significant growth due to the increasing incidence of cancer globally and the continuous advancements in precision medicine. These inhibitors have shown promising results in the treatment of ovarian, breast, and prostate cancers, among others. The market's expansion is further fuelled by ongoing research and development activities, with pharmaceutical companies actively investing in novel PARP inhibitors and combination therapies to enhance treatment efficacy.



Global PARP (Poly ADP-ribose Polymerase) Inhibitors report scope and segmentation.

Report Attribute


Estimated Market Value (2023)

USD 8.36 billion

Projected Market Value (2032)

USD 21.52 billion

Base Year


Forecast Years

2024 – 2032

Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Based on By Drugs Type, By Indication Type, End Users, Distribution Channel & Region.

Segments Covered

By Drugs Type, By Indication Type, End Users, Distribution Channel & By Region.

Forecast Units

Value (USD Billion or Million), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2024 to 2032.

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others.

Report Coverage

Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis.

Delivery Format

Delivered as an attached PDF and Excel through email, according to the purchase option.


Global PARP (Poly ADP-ribose Polymerase) Inhibitors dynamics

One major factor driving the need for novel treatments like PARP inhibitors is the rising incidence of cancer in the world. The positive trajectory of the market is attributed to advancements in precision medicine and the growing comprehension of genetic factors that influence cancer susceptibility. Notably, the widespread occurrence of BRCA gene mutations, linked to diverse forms of cancer, stimulates the uptake of PARP inhibitors, given their notable effectiveness in treating BRCA-mutated cancers.

A significant dynamic is the continuous research and development that pharmaceutical companies engage in to improve the therapeutic profile of currently available PARP inhibitors and create new compounds. Industry participants can share resources and expertise through strategic collaborations and partnerships, which promote innovation and increase market competitiveness. The approval of new indications and formulations influences market expansion, and regulatory dynamics are crucial.

However, the market faces challenges such as high development costs, which may impede the pace of innovation. Patent expirations pose threats to established players, opening opportunities for generic competition. Additionally, concerns regarding potential side effects and the need for robust clinical evidence continue to shape the risk-benefit profiles of PARP inhibitors. Despite these challenges, the overall market dynamics remain positive, driven by a strong commitment to addressing unmet medical needs in oncology and a continuous focus on improving patient outcomes through targeted therapies.


Global PARP (Poly ADP-ribose Polymerase) Inhibitors drivers

  • Increasing Incidence of Cancer and Genetic Factors

The market for PARP inhibitors is significantly influenced by the rising incidence of cancer worldwide. Since cancer is still the primary cause of morbidity and death, there is an increasing need for efficient, targeted treatments like PARP inhibitors. Furthermore, the use of PARP inhibitors is accelerated by the discovery of genetic variables, specifically mutations in the BRCA gene, associated with a variety of malignancies. These inhibitors have been shown to be more effective in tumours that lack DNA repair mechanisms, which makes them an essential part of the treatment regimen for some types of cancer. Finding patient populations that will benefit most from PARP inhibitor therapies is made easier by our growing understanding of the molecular causes of cancer.

  • Advancements in Precision Medicine and Personalized Therapeutics

The development and use of PARP inhibitors are motivated by the continuous developments in precision medicine. PARP inhibitors provide an individualised approach that is consistent with the tenets of personalised therapeutics, with an emphasis on customising treatments based on unique patient characteristics. The overall effectiveness of PARP inhibitors is increased by the capacity to identify patients with particular genetic mutations and match them with customised treatments. Pharmaceutical companies are encouraged to invest in the development of next-generation PARP inhibitors and combination therapies as a result of this paradigm shift towards personalised medicine, which also improves patient outcomes. The integration of PARP inhibitors into precision medicine approaches is further supported by the changing landscape of molecular diagnostics.



  • High Development Costs and Market Competition

One of the main obstacles to the market's expansion is the high expense of PARP inhibitor research, development, and clinical trials. Due to the intricate nature of cancer treatments, lengthy and expensive testing procedures are necessary, which affects PARP inhibitors' general accessibility and affordability. Furthermore, the competitive environment makes it more difficult for pharmaceutical companies to make ends meet, which puts pressure on prices and may prevent new competitors from entering the market. These difficulties might slow down the rate of advancement and restrict the range of patients for whom PARP inhibitors are available.

  • Patent Expirations and Generic Competition

Existing PARP inhibitors face a constraint in the form of generic competition due to the impending threat of patent expirations. Generic versions of products may become available once patents expire, which result in price erosion and a possible loss of market could share for original manufacturers. This dynamic affects revenue streams and emphasises the necessity of ongoing innovation to keep one step ahead of generic competitors. To increase the market exclusivity of their PARP inhibitors and lessen the impact of generic alternatives, pharmaceutical companies must strategically use lifecycle management, such as obtaining new indications or formulations.



  • Expansion of Indications and Combination Therapies

An opportunity lies in the exploration of new indications and combination therapies for PARP inhibitors. Beyond their established efficacy in breast and ovarian cancers, ongoing research opens avenues for expanding the use of PARP inhibitors in other cancer types. Additionally, combining PARP inhibitors with other targeted agents or traditional chemotherapy offers the potential for synergistic effects, enhancing overall treatment outcomes. Pharmaceutical companies have the opportunity to invest in clinical trials to demonstrate the broader utility of PARP inhibitors, thereby capturing new market segments and increasing the therapeutic value of these drugs.


Segment Overview

  • By Drug Types

The market segments based on drug types include Talazoparib, Veliparib, Olaparib, and others. Talazoparib, a potent PARP inhibitor, has shown efficacy in various cancers, particularly breast cancer. Veliparib is recognized for its potential in combination therapies, enhancing the effectiveness of standard treatments. Olaparib, one of the pioneering PARP inhibitors, is widely used across multiple cancer indications. The "others" category encompasses emerging PARP inhibitors, showcasing the industry's commitment to innovation and expanding treatment options.

  • By Indication Types

The indication types segment encompasses Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, and others. PARP inhibitors have gained prominence in ovarian cancer treatment, especially in patients with BRCA mutations. Fallopian tube cancer, closely related to ovarian cancer, presents another target for PARP inhibitor therapies. Breast cancer, with its diverse subtypes, benefits from the precision of PARP inhibitors in cases with specific genetic alterations. The "others" category denotes the potential for broader applications in various cancer types as research continues to uncover new opportunities.

  • By End-Users

End-users in the PARP inhibitors market include Hospitals, Homecare, Specialty Clinics, and others. Hospitals serve as major distribution points for PARP inhibitors, offering comprehensive cancer care. Homecare settings provide opportunities for patients to receive treatment in the comfort of their homes, promoting convenience. Specialty clinics, with their focus on oncology, play a crucial role in the administration of PARP inhibitors. The "others" category may include academic medical centers or research institutions contributing to patient care and advancements in PARP inhibitor therapies.

  • By Distribution Channels

The distribution channels segment involves Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and others. Hospital pharmacies are central in dispensing PARP inhibitors within healthcare facilities. Online pharmacies offer a convenient option for patients to access these medications. Retail pharmacies serve as community-based outlets for PARP inhibitor distribution. The others category might include specialty distributors or collaborative distribution models aiming to optimize accessibility and patient adherence to PARP inhibitor therapies.


Global PARP (Poly ADP-ribose Polymerase) Inhibitors Overview by Region

North America, comprising the United States and Canada, dominates the market owing to advanced healthcare facilities, high cancer incidence rates, and early adoption of innovative therapies. The region is a hub for pharmaceutical research and development, fostering a competitive environment among key market players. Additionally, regulatory approvals for PARP inhibitors in various indications contribute to the robust market growth in North America.

In Europe, countries such as the United Kingdom, Germany, and France play a pivotal role in the PARP inhibitors market. The European Medicines Agency (EMA) approvals and collaborations with research institutions drive advancements in the understanding of genetic factors influencing cancer, influencing the adoption of PARP inhibitors. The region's emphasis on personalized medicine and well-established healthcare systems further supports the integration of these inhibitors into standard cancer treatment protocols.

The Asia-Pacific region is witnessing significant growth, propelled by rising cancer incidences, improving healthcare infrastructure, and increasing awareness of advanced cancer therapies. Countries like China and Japan are key contributors, with a growing focus on precision medicine and the expansion of pharmaceutical research activities. Strategic partnerships between international pharmaceutical companies and local entities aim to enhance market access and capitalize on the region's untapped potential.



Global PARP (Poly ADP-ribose Polymerase) Inhibitors market competitive landscape

Leading players such as AstraZeneca, GlaxoSmithKline, Pfizer, and Clovis Oncology dominate the market with their well-established PARP inhibitor portfolios. AstraZeneca's Olaparib, marketed as Lynparza, has been a trailblazer in the field, securing approvals across various cancer indications, including ovarian and breast cancers. GlaxoSmithKline's Zejula (Niraparib) has also garnered attention for its efficacy in ovarian cancer, while Pfizer's Talzenna (Talazoparib) demonstrates significant potential, especially in breast cancer treatment.

The competitive landscape is marked by strategic collaborations and partnerships aimed at expanding product portfolios and accessing new markets. AstraZeneca, for instance, has engaged in collaborations with Merck to explore the synergistic effects of combining PARP inhibitors with immunotherapies. Clovis Oncology has strategically focused on label expansions and clinical trials to enhance the therapeutic applications of its PARP inhibitor, Rubraca (Rucaparib).


Global PARP (Poly ADP-ribose Polymerase) Inhibitors Recent Developments

  • Feb 2023, Pfizer has reported positive outcomes from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor. The study, conducted in combination with XTANDI (enzalutamide), reveals a statistically significant and clinically meaningful enhancement in radiographic progression-free survival (rPFS) when compared to a placebo plus XTANDI. This improvement is observed in men diagnosed with metastatic castration-resistant prostate cancer (mCRPC), regardless of the presence of homologous recombination repair (HRR) gene mutations.


Scope of global PARP (Poly ADP-ribose Polymerase) Inhibitors report

Global PARP (Poly ADP-ribose Polymerase) Inhibitors report segmentation



By Drugs Type

  • Talazoparib
  • Veliparib
  • Olaparib
  • Others

By Indication Type

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Breast Cancer
  • Others

By End-User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

By Geography

  • North America (USA, and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Customization Scope

  • Available upon request


  • Available upon request


Objectives of the Study

The objectives of the study are summarized in 5 stages. They are as mentioned below:

  • Global PARP (Poly ADP-ribose Polymerase) Inhibitors size and forecast: To identify and estimate the market size for global PARP (Poly ADP-ribose Polymerase) Inhibitors market segmented by Drugs Type, By Indication Type, End Users, Distribution Channel and by region. Also, to understand the consumption/ demand created by consumers between 2024 and 2032.
  • Market Landscape and Trends: To identify and infer the drivers, restraints, opportunities, and challenges for global PARP (Poly ADP-ribose Polymerase) Inhibitors
  • Market Influencing Factors: To find out the factors which are affecting the market of global PARP (Poly ADP-ribose Polymerase) Inhibitors among consumers.
  • Company Profiling:  To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company's past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.

Research Methodology

Our research methodology has always been the key differentiating reason which sets us apart in comparison from the competing organizations in the industry. Our organization believes in consistency along with quality and establishing a new level with every new report we generate; our methods are acclaimed and the data/information inside the report is coveted. Our research methodology involves a combination of primary and secondary research methods. Data procurement is one of the most extensive stages in our research process. Our organization helps in assisting the clients to find the opportunities by examining the market across the globe coupled with providing economic statistics for each and every region.  The reports generated and published are based on primary & secondary research. In secondary research, we gather data for global Market through white papers, case studies, blogs, reference customers, news, articles, press releases, white papers, and research studies. We also have our paid data applications which includes hoovers, Bloomberg business week, Avention, and others.

Data Collection

Data collection is the process of gathering, measuring, and analyzing accurate and relevant data from a variety of sources to analyze market and forecast trends. Raw market data is obtained on a broad front. Data is continuously extracted and filtered to ensure only validated and authenticated sources are considered. Data is mined from a varied host of sources including secondary and primary sources.

Primary Research

After the secondary research process, we initiate the primary research phase in which we interact with companies operating within the market space. We interact with related industries to understand the factors that can drive or hamper a market. Exhaustive primary interviews are conducted. Various sources from both the supply and demand sides are interviewed to obtain qualitative and quantitative information for a report which includes suppliers, product providers, domain experts, CEOs, vice presidents, marketing & sales directors, Type & innovation directors, and related key executives from various key companies to ensure a holistic and unbiased picture of the market. 

Secondary Research

A secondary research process is conducted to identify and collect information useful for the extensive, technical, market-oriented, and comprehensive study of the market. Secondary sources include published market studies, competitive information, white papers, analyst reports, government agencies, industry and trade associations, media sources, chambers of commerce, newsletters, trade publications, magazines, Bloomberg BusinessWeek, Factiva, D&B, annual reports, company house documents, investor presentations, articles, journals, blogs, and SEC filings of companies, newspapers, and so on. We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

Top-Down Approach & Bottom-Up Approach

In the top – down approach, the Global Batteries for Solar Energy Storage Market was further divided into various segments on the basis of the percentage share of each segment. This approach helped in arriving at the market size of each segment globally. The segments market size was further broken down in the regional market size of each segment and sub-segments. The sub-segments were further broken down to country level market. The market size arrived using this approach was then crosschecked with the market size arrived by using bottom-up approach.

In the bottom-up approach, we arrived at the country market size by identifying the revenues and market shares of the key market players. The country market sizes then were added up to arrive at regional market size of the decorated apparel, which eventually added up to arrive at global market size.

This is one of the most reliable methods as the information is directly obtained from the key players in the market and is based on the primary interviews from the key opinion leaders associated with the firms considered in the research. Furthermore, the data obtained from the company sources and the primary respondents was validated through secondary sources including government publications and Bloomberg.

Market Analysis & size Estimation

Post the data mining stage, we gather our findings and analyze them, filtering out relevant insights. These are evaluated across research teams and industry experts. All this data is collected and evaluated by our analysts. The key players in the industry or markets are identified through extensive primary and secondary research. All percentage share splits, and breakdowns have been determined using secondary sources and verified through primary sources. The market size, in terms of value and volume, is determined through primary and secondary research processes, and forecasting models including the time series model, econometric model, judgmental forecasting model, the Delphi method, among Flywheel Energy Storage. Gathered information for market analysis, competitive landscape, growth trends, product development, and pricing trends is fed into the model and analyzed simultaneously.

Quality Checking & Final Review

The analysis done by the research team is further reviewed to check for the accuracy of the data provided to ensure the clients’ requirements. This approach provides essential checks and balances which facilitate the production of quality data. This Type of revision was done in two phases for the authenticity of the data and negligible errors in the report. After quality checking, the report is reviewed to look after the presentation, Type and to recheck if all the requirements of the clients were addressed.

Frequently Asked Questions

Global PARP (Poly ADP-ribose Polymerase) Inhibitors forecast period is 2024 - 2032
According to global PARP (Poly ADP-ribose Polymerase) Inhibitors research, the market is expected to grow at a CAGR of ~11.08% over the next eight years.
The possible segments in global PARP (Poly ADP-ribose Polymerase) Inhibitors are based on by Drugs Type, By Indication Type, End Users, Distribution Channel & by region.
The expected market size for Global PARP (Poly ADP-ribose Polymerase) Inhibitors is USD 8.36 billion in 2023.
The major players in the market are AstraZeneca (U.S.), AbbVie Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), Merck & Co. Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Myriad Genetics, Inc. (U.S.) and CLOVIS ONCOLOGY (U.S.).